A promiscuous kinase inhibitor delineates the conspicuous structural features of protein kinase CK2a1.


Journal

Acta crystallographica. Section F, Structural biology communications
ISSN: 2053-230X
Titre abrégé: Acta Crystallogr F Struct Biol Commun
Pays: United States
ID NLM: 101620319

Informations de publication

Date de publication:
01 Jul 2019
Historique:
received: 22 05 2019
accepted: 22 06 2019
entrez: 9 7 2019
pubmed: 10 7 2019
medline: 14 1 2020
Statut: ppublish

Résumé

Protein kinase CK2a1 is a serine/threonine kinase that plays a crucial role in the growth, proliferation and survival of cells and is a well known target for tumour and glomerulonephritis therapies. Here, the crystal structure of the kinase domain of CK2a1 complexed with 5-iodotubercidin (5IOD), an ATP-mimetic inhibitor, was determined at 1.78 Å resolution. The structure shows distinct structural features and, in combination with a comparison of the crystal structures of five off-target kinases complexed with 5IOD, provides valuable information for the development of highly selective inhibitors.

Identifiants

pubmed: 31282872
pii: S2053230X19008951
doi: 10.1107/S2053230X19008951
pmc: PMC6613443
doi:

Substances chimiques

Protein Kinase Inhibitors 0
5-iodotubercidin 24386-93-4
CSNK2A1 protein, human EC 2.7.11.1
Casein Kinase II EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Tubercidin M351LCX45Y

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

515-519

Références

Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5
pubmed: 20057045
Cancer Res. 2010 Dec 15;70(24):10288-98
pubmed: 21159648
Bioorg Med Chem Lett. 2016 Feb 1;26(3):955-958
pubmed: 26733474
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Angew Chem Int Ed Engl. 2018 Jun 11;57(24):7220-7224
pubmed: 29601130
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1123-7
pubmed: 18983981
Chem Sci. 2018 Feb 20;9(11):3041-3049
pubmed: 29732088
Trends Biochem Sci. 2011 Feb;36(2):65-77
pubmed: 20971646
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7736-41
pubmed: 15897466
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20198-203
pubmed: 19918057
Biochim Biophys Acta. 2008 Jan;1784(1):33-47
pubmed: 17931986
Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3
pubmed: 19414254
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
Biochem J. 1994 Apr 1;299 ( Pt 1):123-8
pubmed: 8166629
Biochem Biophys Res Commun. 2006 Aug 4;346(3):840-4
pubmed: 16782058
Nat Struct Biol. 1999 Dec;6(12):1100-3
pubmed: 10581548
Science. 1988 Jun 17;240(4859):1648-52
pubmed: 3381086
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6557-60
pubmed: 19857964
Chem Biol. 2011 Aug 26;18(8):966-75
pubmed: 21867912
J Synchrotron Radiat. 2013 Nov;20(Pt 6):974-9
pubmed: 24121351

Auteurs

Masato Tsuyuguchi (M)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Tetsuko Nakaniwa (T)

Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan.

Masaaki Sawa (M)

Carna BioSciences, Kobe, Hyogo 650-0047, Japan.

Isao Nakanishi (I)

Department of Pharmaceutical Sciences, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, Japan.

Takayoshi Kinoshita (T)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH